The next generation of digital immunoassay technology, delivering femtogram-level sensitivity for early-stage Alzheimer’s detection and clinical research.
The Diagnostic Challenge In the fight against neurodegenerative diseases like Alzheimer’s, Multiple Sclerosis (MS), and Traumatic Brain Injury (TBI), time is the most critical variable. Traditional methods often fail to detect pathology before irreversible damage occurs. The Inspirer DX Analyzer changes this trajectory.
Why Inspirer DX Leads the Field
- Single-Molecule Digital Immunochip Technology: By utilizing advanced digital immunoassay, our platform quantifies protein markers (Aβ40/42, NfL) with unparalleled accuracy, even at the lowest femtogram concentrations.
- Clinical-Grade Early Detection: Transform your laboratory into a hub for precision medicine. Identify disease progression at the pre-clinical stage, allowing for earlier patient intervention and better clinical outcomes.
- Non-Invasive Protocol: Streamline patient care with a high-accuracy, non-invasive diagnostic process that replaces outdated, complex procedures.
Empowering Professionals Whether for clinical diagnostics or pharmaceutical research, the Inspirer DX Analyzer provides the data integrity you need to drive informed medical decisions.
Ready to upgrade your diagnostic capabilities?
